Panel-Track PMA Supplements: When FDA Waives Advisory Review
For regulatory and clinical teams managing Class III device programs, the distinction between a panel-track PMA supplement and a mandatory advisory committee convening carries significant strategic and timeline implications. Misunderstanding this distinction can lead to over-preparation for a panel meeting that will never occur, or—more consequentially—under-preparation for one that will.
This analysis examines the statutory and regulatory basis for FDA's discretion over advisory panel referrals, reviews how that discretion is exercised in practice across multiple device review panels, and clarifies what the panel-track designation actually signals about evidentiary standards versus procedural requirements.
Want to ask Rhizome your own regulatory questions? Try it for free.
Can a panel-track PMA proceed without an FDA advisory panel review?
Short answer: Yes. Advisory panel (advisory committee) referral is discretionary, not mandatory, for premarket approval applications. FDA routinely approves original PMAs and panel-track PMA supplements without convening an advisory panel when the application does not raise new safety or effectiveness questions relative to what the relevant device panel has already considered. The label "panel-track" describes the supplement's evidentiary weight, not a guarantee that a panel meeting will actually be held.
The two things "panel track" can mean
It helps to separate two uses of the term, because the question sits at their intersection.
-
Panel-track PMA supplement. This is a specific PMA supplement type used when a change is significant enough to warrant substantial (usually clinical) evidence, such as a new indication or a major design/model change 23. The reviewed documents show it applied to submissions supported by prospective clinical studies (for example, a "Panel Track PMA Supplement" whose database included 103 patients from a prospective single-arm study) 2 and to a new model/indication that "received marketing approval... under Panel-Track Supplement" 3. The name reflects the historical idea that such changes are the kind FDA could send to a panel. It does not mean a panel meeting is required.
-
Original PMA. The classic first-time approval of a Class III device, which is the setting where FDA most often decides whether to convene a device advisory panel.
In both settings the referral decision is discretionary.
The statutory basis: referral is discretionary
PMA approval orders tie the decision directly to FDA's discretion under section 515(c)(2) of the Federal Food, Drug, and Cosmetic Act (as amended by the Safe Medical Devices Act of 1990). The recorded language is consistent: "Based on the regulatory discretion provided in section 515(c)(2)... this PMA was not referred... for review and recommendation" 8081, and "In accordance with the provisions of section 515(c)(2)... this PMA was not referred... because the information in the PMA substantially duplicates information previously reviewed by this panel" 82838485. None of the reviewed documents describe panel referral as mandatory 808182838485.
What FDA actually writes when it skips the panel
The near-universal formulation in the SSED is some version of:
"this PMA was not referred to the [named] Panel, an FDA advisory committee, for review and recommendation because the information in the PMA substantially duplicates information previously reviewed by this panel." 456711
FDA also uses closely related rationales, such as the application raising no new questions, or the key issues having been vetted through bench and clinical testing. Selected examples from the PMA record:
| PMA number | Device | Recorded rationale for no panel | Cite |
|---|---|---|---|
| P100040 | Valiant Thoracic Stent Graft System | "substantially duplicates information previously reviewed by this panel" (Circulatory System Devices Panel) | 53 |
| P230030 | FARAPULSE Pulsed Field Ablation System | not referred because the "pertinent issues for safety and effectiveness of a pulsed field ablation system have been vetted through comprehensive bench and clinical evaluations" | 55 |
| P210001 | VENTANA MMR RxDx Panel | not referred because the PMA "did not raise any new safety and effectiveness questions compared with information previously reviewed by this panel" | 33 |
| P250027 | Guardant360 Liquid CDx | "substantially duplicates information previously reviewed by this panel" (Molecular and Clinical Genetics Panel) | 54 |
| P110039 | EXABLATE | "This application was not referred to the General and Plastic Surgery Devices Advisory Panel for review and recommendation." | 68 |
| P200036 | eCoin Peripheral Neurostimulator | "substantially duplicates information previously reviewed by this panel" (Gastroenterology/Urology Panel) | 57 |
| P250028 | Synergy Disc | "substantially duplicates information previously reviewed by this panel" (Orthopaedic and Rehabilitation Devices Panel) | 66 |
This pattern spans many device types and panels (immunology, microbiology, clinical chemistry, molecular/clinical genetics, circulatory system, gastroenterology-urology, orthopedic), which is why it is fair to describe panel-free PMA approval as routine rather than exceptional 456781115283345545557596266.
Notably, the FARAPULSE pulsed-field ablation approval shows that even a substantive, technologically significant device can be cleared through the PMA route without a panel meeting when FDA judges the safety and effectiveness questions adequately addressed by bench and clinical data 55.
When FDA does convene a device panel
Panels are used selectively, not automatically for every Class III PMA. The advisory committee record shows meetings convened for particular high-interest PMAs, especially "first-of-a-kind" devices, and for classification or reclassification questions (for example, whether products should sit in class I, II, or III, or move from class III to 510(k)) 777879. In one PMA meeting the committee was set to "discuss, make recommendations, and vote on information regarding the premarket approval application (PMA)" for a first-of-a-kind device 77.
The PMA files also capture the contrast directly. Where an application is genuinely novel, FDA does convene a panel: the SSED for a later, similar submission explains it was not referred precisely because the technology had already been vetted "when the panel met on October 20, 2022... to discuss the AvertD test," including the recorded panel vote 14. And at least one reviewed approval expressly states the PMA was referred to the panel (Sculptra / Sculptra Aesthetic), confirming referral still happens where warranted 63.
Practical read for a submission team
- Do not assume a "panel-track" supplement or a novel PMA will get, or avoid, a panel. The decision is FDA's under section 515(c)(2), and it turns on whether your application raises new safety/effectiveness questions the relevant panel has not already addressed 8082.
- The strongest predictor of no panel in the record is substantial duplication of, or no new questions beyond, previously panel-reviewed information 41133. First-of-a-kind technology and open scientific questions push toward a panel 1477.
- Even a significant new-technology PMA can proceed without a panel if the safety/effectiveness issues are considered resolved by bench and clinical evidence, as in the FARAPULSE PFA approval 55.
Limitations
These conclusions are grounded in the approval-era SSED and approval-order language in the PMA database and the advisory committee meeting record, which state FDA's rationale succinctly rather than reproducing full statutory or guidance text. The documents confirm that referral is discretionary and that panel-free approval is common, but they do not provide a numeric rate of panel vs. no-panel decisions, nor a complete definition of the panel-track supplement trigger. For a device-specific read (for example, whether your particular first-of-a-kind indication is likely to be paneled), a targeted look at the closest predicate PMAs and any related panel meetings is the next step.